- Home
- SNEX vs ACAD Comparison
SNEX vs ACAD Comparison
Compare SNEX & ACAD Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- SNEX
- ACAD
- Stock Information
- Founded
- SNEX 1924
- ACAD 1993
- Country
- SNEX United States
- ACAD United States
- Employees
- SNEX N/A
- ACAD N/A
- Industry
- SNEX Investment Bankers/Brokers/Service
- ACAD Biotechnology: Pharmaceutical Preparations
- Sector
- SNEX Finance
- ACAD Health Care
- Exchange
- SNEX Nasdaq
- ACAD Nasdaq
- Market Cap
- SNEX 3.3B
- ACAD 2.9B
- IPO Year
- SNEX 1994
- ACAD 2004
- Fundamental
- Price
- SNEX $95.89
- ACAD $17.67
- Analyst Decision
- SNEX
- ACAD Buy
- Analyst Count
- SNEX 0
- ACAD 19
- Target Price
- SNEX N/A
- ACAD $26.44
- AVG Volume (30 Days)
- SNEX 156.9K
- ACAD 1.5M
- Earning Date
- SNEX 02-04-2025
- ACAD 11-06-2024
- Dividend Yield
- SNEX N/A
- ACAD N/A
- EPS Growth
- SNEX 6.85
- ACAD N/A
- EPS
- SNEX 7.96
- ACAD 0.78
- Revenue
- SNEX $98,704,300,000.00
- ACAD $929,236,000.00
- Revenue This Year
- SNEX N/A
- ACAD $37.34
- Revenue Next Year
- SNEX N/A
- ACAD $7.25
- P/E Ratio
- SNEX $11.99
- ACAD $22.41
- Revenue Growth
- SNEX 64.52
- ACAD 47.06
- 52 Week Low
- SNEX $61.68
- ACAD $14.15
- 52 Week High
- SNEX $106.77
- ACAD $32.59
- Technical
- Relative Strength Index (RSI)
- SNEX 36.80
- ACAD 54.79
- Support Level
- SNEX $95.27
- ACAD $16.78
- Resistance Level
- SNEX $103.92
- ACAD $17.60
- Average True Range (ATR)
- SNEX 2.09
- ACAD 0.68
- MACD
- SNEX -1.42
- ACAD -0.03
- Stochastic Oscillator
- SNEX 2.64
- ACAD 45.21
About SNEX StoneX Group Inc.
StoneX Group Inc is a Global brokerage and financial services firm. Its service offerings are execution, OTC / Market-Making, advisory services, Global payment solutions, market intelligence, Physical Trading and clearing services. The firm operates in four segments: commercial, Institutional, Retail, and Global Payments. Its customers include governmental and nongovernmental organizations, and commercial banks, brokers, institutional investors, and investment banks. The company operates in United States, South America, Europe, Middle East and Asia and other countries, out of which majority revenue is generates from Middle East and Asia Region.
About ACAD ACADIA Pharmaceuticals Inc.
Acadia Pharmaceuticals Inc is a biotechnology company that develops and commercializes biopharmaceutical products to address central nervous system disorders. The company aims to discover small molecules drugs that address disorders such as Parkinson's, Alzheimer's, and schizophrenia. Acadia also seeks to in-license or acquire complementary products and candidates. The company's patent applications claim proprietary technology, including novel methods of screening and chemical synthetic methods, novel drug targets, and novel compounds identified using its technology.